JPY 2097.0
(0.58%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 697 Million JPY | 41.96% |
2022 | 491 Million JPY | 73.5% |
2021 | 283 Million JPY | 37.38% |
2020 | 206 Million JPY | -36.02% |
2019 | 322 Million JPY | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 245 Million JPY | 744.74% |
2023 Q3 | 262 Million JPY | 35.05% |
2023 Q2 | 194 Million JPY | -30.47% |
2023 Q4 | -38 Million JPY | -114.5% |
2023 FY | 697 Million JPY | 41.96% |
2023 Q1 | 279 Million JPY | 458.0% |
2022 Q3 | 181 Million JPY | 74.04% |
2022 FY | 491 Million JPY | 73.5% |
2022 Q4 | 50 Million JPY | -72.38% |
2022 Q2 | 104 Million JPY | 0.0% |
2021 FY | 283 Million JPY | 37.38% |
2020 FY | 206 Million JPY | -36.02% |
2019 FY | 322 Million JPY | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 3.2 Billion JPY | 78.253% |
Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 99.516% |
Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 100.221% |
Shionogi & Co., Ltd. | 162.03 Billion JPY | 99.57% |
Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | -539.69% |
Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 97.304% |
Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 91.315% |
Eisai Co., Ltd. | 42.4 Billion JPY | 98.356% |
Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 95.01% |
Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 84.671% |
Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | 49.383% |
Nippon Chemiphar Co., Ltd. | -180 Million JPY | 487.222% |
Tsumura & Co. | 16.7 Billion JPY | 95.828% |
Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 93.754% |
Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 83.078% |
Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 95.69% |
Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 79.709% |
Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 90.985% |
KYORIN Holdings, Inc. | 5.32 Billion JPY | 86.903% |
Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 114.242% |
Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | 78.847% |
SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 135.51% |
MedRx Co., Ltd | -932 Million JPY | 174.785% |
Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 81.533% |
Solasia Pharma K.K. | -1.11 Billion JPY | 162.68% |
Modalis Therapeutics Corporation | -2.39 Billion JPY | 129.141% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 90.762% |
Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 94.911% |
Cyfuse Biomedical K.K. | -589.21 Million JPY | 218.294% |
Toho Holdings Co., Ltd. | 20.65 Billion JPY | 96.626% |
Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | 76.344% |